Engineered small extracellular vesicles for the neutralization of SARS-CoV-2

Characterizing these engineered sEVs, the researchers demonstrated that the soluble angiotensin-converting enzyme 2 (sACE-2) loaded sEV successfully binds and thus inhibits the entry of wild-type SARS-CoV-2 as well as its variants, protecting against SARS-CoV-2 infection. They also demonstrated the therapeutic efficacy of these engineered sEVs in vivo.